“Savoir s'étonner à propos est le premier pas fait sur la route de la découverte”
Louis Pasteur
Pierre WEIGEL
Maître de conférences Université
août 2024
section 64
Équipe : |
Thèmes de recherche
1989 : Assistant Associé à l’Université de Rennes I. Etude de l’intégrité cellulaire et tissulaire d’organismes végétaux confrontés à un stress salin – Laboratoire du Professeur F. Larher. (avril à septembre 1989).
1988-89 : Associate Research Assistant au University College London, Etude de l’interaction plante hôte/Striga – Laboratoire du Professeur G. Stewart.
1988 : Assistant Associé à l’Université de Rennes I. Etude de l’adaptation métabolique de plantes supérieures soumises à un stress par le sel – Laboratoire du Professeur F. Larher.
1989-90 : Chercheur à l’Institut de Recherche et de Transfert des Lipides à Rennes. Etude d’une D12 désaturase végétale.
1990 : Directeur adjoint de l’institut de Recherche et de Transfert des Lipides à Rennes
1990- : Maître de conférences en biochimie à la Faculté des Sciences et des Techniques de Nantes (1er oct 1990) : Thématiques de recherches sur l’étude des cholinestérases intestinales et sur la régulation de la voie de biosynthèse de l’arginine chez les bactéries thermophiles.
Actuellement rattaché à l’UMR CNRS n°6286 Fonctionnalité et Ingénierie des Protéines (UFIP) : Recherche de nouveaux inhibiteurs d’enzymes impliqués dans différentes pathologies humaines
Projets
Parcours universitaire
1984-88 : Visiting Research Specialist au Plant Research Laboratory (PRL) Michigan State University (USA)
1988 : Doctorat de l’université de Rennes 1 portant sur le sujet suivant : “Recherches sur les mécanismes chloroplastiques d’oxydation de la choline en glycine bétaïne chez Spinacia oleracea”.
Publications
2 publications
Mauro, E; Lapaillerie, D; Tumiotto, C; Charlier, Cathy; Martins, F; Sousa, S F; Métifiot, M; Weigel, Pierre; Yamatsugu, K; Kanai, M; Munier-Lehmann, H; Richetta, C; Maisch, M; Dutrieux, J; Batisse, J; Ruff, M; Delelis, O; Lesbats, P; Parissi, V
Modulation of the functional interfaces between retroviral intasomes and the human nucleosome Article de journal
Dans: mBio, p. e0108323, 2023, ISSN: 2150-7511.
@article{pmid37382440,
title = {Modulation of the functional interfaces between retroviral intasomes and the human nucleosome},
author = {E Mauro and D Lapaillerie and C Tumiotto and Cathy Charlier and F Martins and S F Sousa and M Métifiot and Pierre Weigel and K Yamatsugu and M Kanai and H Munier-Lehmann and C Richetta and M Maisch and J Dutrieux and J Batisse and M Ruff and O Delelis and P Lesbats and V Parissi},
doi = {10.1128/mbio.01083-23},
issn = {2150-7511},
year = {2023},
date = {2023-06-01},
urldate = {2023-06-01},
journal = {mBio},
pages = {e0108323},
abstract = {Infection by retroviruses as HIV-1 requires the stable integration of their genome into the host cells. This process needs the formation of integrase (IN)-viral DNA complexes, called intasomes, and their interaction with the target DNA wrapped around nucleosomes within cell chromatin. To provide new tools to analyze this association and select drugs, we applied the AlphaLISA technology to the complex formed between the prototype foamy virus (PFV) intasome and nucleosome reconstituted on 601 Widom sequence. This system allowed us to monitor the association between both partners and select small molecules that could modulate the intasome/nucleosome association. Using this approach, drugs acting either on the DNA topology within the nucleosome or on the IN/histone tail interactions have been selected. Within these compounds, doxorubicin and histone binders calixarenes were characterized using biochemical, molecular simulations and cellular approaches. These drugs were shown to inhibit both PFV and HIV-1 integration . Treatment of HIV-1-infected PBMCs with the selected molecules induces a decrease in viral infectivity and blocks the integration process. Thus, in addition to providing new information about intasome-nucleosome interaction determinants, our work also paves the way for further unedited antiviral strategies that target the final step of intasome/chromatin anchoring. IMPORTANCE In this work, we report the first monitoring of retroviral intasome/nucleosome interaction by AlphaLISA. This is the first description of the AlphaLISA application for large nucleoprotein complexes (>200 kDa) proving that this technology is suitable for molecular characterization and bimolecular inhibitor screening assays using such large complexes. Using this system, we have identified new drugs disrupting or preventing the intasome/nucleosome complex and inhibiting HIV-1 integration both and in infected cells. This first monitoring of the retroviral/intasome complex should allow the development of multiple applications including the analyses of the influence of cellular partners, the study of additional retroviral intasomes, and the determination of specific interfaces. Our work also provides the technical bases for the screening of larger libraries of drugs targeting specifically these functional nucleoprotein complexes, or additional nucleosome-partner complexes, as well as for their characterization.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Demeyer, Alexandre; Fonteneau, Lucie; Liennard, Marion; Foyer, Claire; Weigel, Pierre; Laurent, Adèle; Lebreton, Jacques; Fleury, Fabrice; Mathé-Allainmat, Monique
Synthesis and Biological Evaluation of DIDS Analogues as Efficient Inhibitors of RAD51 Involved in Homologous Recombination Article de journal
Dans: Bioorg Med Chem Lett, p. 129261, 2023, ISSN: 1464-3405.
@article{pmid36990245,
title = {Synthesis and Biological Evaluation of DIDS Analogues as Efficient Inhibitors of RAD51 Involved in Homologous Recombination},
author = {Alexandre Demeyer and Lucie Fonteneau and Marion Liennard and Claire Foyer and Pierre Weigel and Adèle Laurent and Jacques Lebreton and Fabrice Fleury and Monique Mathé-Allainmat},
url = {hal-04234850v1 },
doi = {10.1016/j.bmcl.2023.129261},
issn = {1464-3405},
year = {2023},
date = {2023-03-01},
urldate = {2023-03-01},
journal = {Bioorg Med Chem Lett},
pages = {129261},
abstract = {RAD51 is a pivotal protein of the homologous recombination DNA repair pathway, and is overexpressed in some cancer cells, disrupting then the efficiency of cancer-treatments. The development of RAD51 inhibitors appears as a promising solution to restore these cancer cells sensitization to radio- or chemotherapy. From a small molecule identified as a modulator of RAD51, the 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), two series of analogues with small or bulky substituents on the aromatic parts of the stilbene moiety were prepared for a structure-activity relationship study. Three compounds, the cyano analogue (12), and benzamide (23) or phenylcarbamate (29) analogues of DIDS were characterized as novel potent RAD51 inhibitors with HR inhibition in the micromolar range.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
1 publication
Lapaillerie, Delphine; Charlier, Cathy; Guyonnet-Dupérat, Véronique; Murigneux, Emilie; Fernandes, Henrique S.; Martins, Fábio G.; Magalhães, Rita P.; Vieira, Tatiana F.; Richetta, Clémence; Subra, Frédéric; Lebourgeois, Samuel; Charpentier, Charlotte; Descamps, Diane; Visseaux, Benoît; Weigel, Pierre; Favereaux, Alexandre; Beauvineau, Claire; Buron, Frédéric; Teulade-Fichou, Marie-Paule; Routier, Sylvain; Gallois-Montbrun, Sarah; Meertens, Laurent; Delelis, Olivier; Sousa, Sérgio F.; Parissi, Vincent
Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces Article de journal
Dans: Antimicrobial Agents and Chemotherapy, vol. 0, no. 0, p. e00083-22, 2022.
@article{doi:10.1128/aac.00083-22,
title = {Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces},
author = {Delphine Lapaillerie and Cathy Charlier and Véronique Guyonnet-Dupérat and Emilie Murigneux and Henrique S. Fernandes and Fábio G. Martins and Rita P. Magalhães and Tatiana F. Vieira and Clémence Richetta and Frédéric Subra and Samuel Lebourgeois and Charlotte Charpentier and Diane Descamps and Benoît Visseaux and Pierre Weigel and Alexandre Favereaux and Claire Beauvineau and Frédéric Buron and Marie-Paule Teulade-Fichou and Sylvain Routier and Sarah Gallois-Montbrun and Laurent Meertens and Olivier Delelis and Sérgio F. Sousa and Vincent Parissi},
url = {https://journals.asm.org/doi/abs/10.1128/aac.00083-22
hal-03826873v1 },
doi = {10.1128/aac.00083-22},
year = {2022},
date = {2022-07-05},
urldate = {2022-07-05},
journal = {Antimicrobial Agents and Chemotherapy},
volume = {0},
number = {0},
pages = {e00083-22},
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent that has caused the current coronavirus disease (COVID) pandemic. Viral infection relies on the viral S (spike) protein/cellular receptor ACE2 interaction. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent that has caused the current coronavirus disease (COVID) pandemic. Viral infection relies on the viral S (spike) protein/cellular receptor ACE2 interaction. Disrupting this interaction would lead to early blockage of viral replication. To identify chemical tools to further study these functional interfaces, 139,146 compounds from different chemical libraries were screened through an S/ACE2 in silico virtual molecular model. The best compounds were selected for further characterization using both cellular and biochemical approaches, reiterating SARS-CoV-2 entry and the S/ACE2 interaction. We report here two selected hits, bis-indolyl pyridine AB-00011778 and triphenylamine AB-00047476. Both of these compounds can block the infectivity of lentiviral vectors pseudotyped with the SARS-CoV-2 S protein as well as wild-type and circulating variant SARS-CoV-2 strains in various human cell lines, including pulmonary cells naturally susceptible to infection. AlphaLISA and biolayer interferometry confirmed a direct inhibitory effect of these drugs on the S/ACE2 association. A specific study of the AB-00011778 inhibitory properties showed that this drug inhibits viral replication with a 50% effective concentration (EC50) between 0.1 and 0.5 μM depending on the cell lines. Molecular docking calculations of the interaction parameters of the molecules within the S/ACE2 complex from both wild-type and circulating variants of the virus showed that the molecules may target multiple sites within the S/ACE2 interface. Our work indicates that AB-00011778 constitutes a good tool for modulating this interface and a strong lead compound for further therapeutic purposes.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
2 publications
Demeyer, Alexandre; Benhelli-Mokrani, Houda; Chénais, B.; Weigel, Pierre; Fleury, Fabrice
Inhibiting homologous recombination by targeting RAD51 protein Article de journal
Dans: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1876, no. 2, p. 188597, 2021, ISSN: 0304419X.
@article{demeyer_inhibiting_2021,
title = {Inhibiting homologous recombination by targeting RAD51 protein},
author = {Alexandre Demeyer and Houda Benhelli-Mokrani and B. Chénais and Pierre Weigel and Fabrice Fleury},
url = {https://linkinghub.elsevier.com/retrieve/pii/S0304419X21000949},
doi = {10.1016/j.bbcan.2021.188597},
issn = {0304419X},
year = {2021},
date = {2021-09-15},
urldate = {2021-09-15},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
volume = {1876},
number = {2},
pages = {188597},
abstract = {Homologous recombination (HR) is involved in repairing DNA double-strand breaks (DSB), the most harmful for the cell. Regulating HR is essential for maintaining genomic stability. In many forms of cancer, overactivation of HR increases tumor resistance to DNA-damaging treatments. RAD51, HR's core protein, is very often overexpressed in these cancers and plays a critical role in cancer cell development and survival. Targeting RAD51 directly to reduce its activity and its expression is therefore one strategy to sensitize and overcome resistance cancer cells to existing DNA-damaging therapies which remains the limiting factor for the success of targeted therapy.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Lapaillerie, Delphine; Charlier, Cathy; Fernandes, Henrique S; Sousa, Sergio F; Lesbats, Paul; Weigel, Pierre; Favereaux, Alexandre; Guyonnet-Duperat, Véronique; Parissi, Vincent
In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion Article de journal
Dans: Viruses, vol. 13, no. 3, p. 365, 2021, ISSN: 1999-4915.
@article{lapaillerie_silico_2021,
title = {In Silico, In Vitro and In Cellulo Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion},
author = {Delphine Lapaillerie and Cathy Charlier and Henrique S Fernandes and Sergio F Sousa and Paul Lesbats and Pierre Weigel and Alexandre Favereaux and Véronique Guyonnet-Duperat and Vincent Parissi},
url = {https://www.mdpi.com/1999-4915/13/3/365},
doi = {10.3390/v13030365},
issn = {1999-4915},
year = {2021},
date = {2021-01-01},
urldate = {2021-04-30},
journal = {Viruses},
volume = {13},
number = {3},
pages = {365},
abstract = {Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the recent coronavirus disease 2019 (COVID-19) pandemic. Productive SARS-CoV-2 infection relies on viral entry into cells expressing angiotensin-converting enzyme 2 (ACE2). Indeed, viral entry into cells is mostly mediated by the early interaction between the viral spike protein S and its ACE2 receptor. The S/ACE2 complex is, thus, the first contact point between the incoming virus and its cellular target; consequently, it has been considered an attractive therapeutic target. To further characterize this interaction and the cellular processes engaged in the entry step of the virus, we set up various in silico, in vitro and in cellulo approaches that allowed us to specifically monitor the S/ACE2 association. We report here a computational model of the SARS-CoV-2 S/ACE2 complex, as well as its biochemical and biophysical monitoring using pulldown, AlphaLISA and biolayer interferometry (BLI) binding assays. This led us to determine the kinetic parameters of the S/ACE2 association and dissociation steps. In parallel to these in vitro approaches, we developed in cellulo transduction assays using SARS-CoV-2 pseudotyped lentiviral vectors and HEK293T-ACE2 cell lines generated in-house. This allowed us to recapitulate the early replication stage of the infection mediated by the S/ACE2 interaction and to detect cell fusion induced by the interaction. Finally, a cell imaging system was set up to directly monitor the S/ACE2 interaction in a cellular context and a flow cytometry assay was developed to quantify this association at the cell surface. Together, these different approaches are available for both basic and clinical research, aiming to characterize the entry step of the original SARS-CoV-2 strain and its variants as well as to investigate the possible chemical modulation of this interaction. All these models will help in identifying new antiviral agents and new chemical tools for dissecting the virus entry step.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
2 publications
Fleury, Fabrice; Demeyer, Alexandre; Weigel, Pierre; Chenais, Benoit; Mathé, Monique; Lebreton, Jacques
Disulfonate stilbenes for use in the treatment of proliferative diseases Patent
WO2020104634A1, 2020.
@patent{demeyer2020,
title = {Disulfonate stilbenes for use in the treatment of proliferative diseases},
author = {Fabrice Fleury and Alexandre Demeyer and Pierre Weigel and Benoit Chenais and Monique Mathé and Jacques Lebreton},
url = {https://worldwide.espacenet.com/patent/search/family/064564793/publication/WO2020104634A1?q=pn%3DWO2020104634A1},
year = {2020},
date = {2020-05-28},
number = {WO2020104634A1},
abstract = {This invention relates to compounds of general formula: wherein R0A and R0B are independently selected from hydrogen and pharmaceutically acceptable cations; and RA and RB are identical and selected from amide, carbamate, sulphonamide, azido, cyano and halide. The invention also relates to a pharmaceutical composition comprising a compound according to the invention. According to an embodiment, the composition further comprises another active ingredient, especially an antineoplastic agent. The invention also relates to a compound or a composition according to the invention for use as a medicament, especially a compound or a composition for use in the treatment of a proliferative disease such as for example cancer.},
keywords = {},
pubstate = {published},
tppubtype = {patent}
}
Aganyants, Hovsep; Weigel, Pierre; Hovhannisyan, Yeranuhi; Lecocq, Michèle; Koloyan, Haykanush; Hambardzumyan, Artur; Hovsepyan, Anichka; Hallet, Jean Noël; Sakanyan, Vehary
Rational engineering of the substrate specificity of a thermostable d-hydantoinase (Dihydropyrimidinase) Article de journal
Dans: High-Throughput, vol. 9, no. 1, 2020, ISSN: 25715135.
@article{Aganyants2020,
title = {Rational engineering of the substrate specificity of a thermostable d-hydantoinase (Dihydropyrimidinase)},
author = {Hovsep Aganyants and Pierre Weigel and Yeranuhi Hovhannisyan and Michèle Lecocq and Haykanush Koloyan and Artur Hambardzumyan and Anichka Hovsepyan and Jean Noël Hallet and Vehary Sakanyan},
doi = {10.3390/ht9010005},
issn = {25715135},
year = {2020},
date = {2020-03-01},
journal = {High-Throughput},
volume = {9},
number = {1},
publisher = {MDPI AG},
abstract = {D-hydantoinases catalyze an enantioselective opening of 5-and 6-membered cyclic structures and therefore can be used for the production of optically pure precursors for biomedical applications. The thermostable D-hydantoinase from Geobacillus stearothermophilus ATCC 31783 is a manganese-dependent enzyme and exhibits low activity towards bulky hydantoin derivatives. Homology modeling with a known 3D structure (PDB code: 1K1D) allowed us to identify the amino acids to be mutated at the substrate binding site and in its immediate vicinity to modulate the substrate specificity. Both single and double substituted mutants were generated by site-directed mutagenesis at appropriate sites located inside and outside of the stereochemistry gate loops (SGL) involved in the substrate binding. Substrate specificity and kinetic constant data demonstrate that the replacement of Phe159 and Trp287 with alanine leads to an increase in the enzyme activity towards D,L-5-benzyl and D,L-5-indolylmethyl hydantoins. The length of the side chain and the hydrophobicity of substrates are essential parameters to consider when designing the substrate binding pocket for bulky hydantoins. Our data highlight that D-hydantoinase is the authentic dihydropyrimidinase involved in the pyrimidine reductive catabolic pathway in moderate thermophiles.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
1 publication
Velic, Denis; Charlier, Cathy; Popova, Milena; Jaunet-Lahary, Titouan; Bouchouireb, Zakaria; Henry, Sébastien; Weigel, Pierre; Masson, Jean-Yves; Laurent, Adèle D; Nabiev, Igor; Fleury, Fabrice
Interactions of the Rad51 inhibitor DIDS with human and bovine serum albumins: Optical spectroscopy and isothermal calorimetry approaches Article de journal
Dans: Biochimie, vol. 167, p. 187–197, 2019, ISSN: 0300-9084.
@article{VELIC2019187,
title = {Interactions of the Rad51 inhibitor DIDS with human and bovine serum albumins: Optical spectroscopy and isothermal calorimetry approaches},
author = {Denis Velic and Cathy Charlier and Milena Popova and Titouan Jaunet-Lahary and Zakaria Bouchouireb and Sébastien Henry and Pierre Weigel and Jean-Yves Masson and Adèle D Laurent and Igor Nabiev and Fabrice Fleury},
url = {http://www.sciencedirect.com/science/article/pii/S0300908419302743},
doi = {https://doi.org/10.1016/j.biochi.2019.09.016},
issn = {0300-9084},
year = {2019},
date = {2019-01-01},
journal = {Biochimie},
volume = {167},
pages = {187--197},
abstract = {Rad51 is a key protein in DNA repair by homologous recombination and an important target for development of drugs in cancer therapy. 4′-diisothiocyanostilbene-2,2′-disulfonic acid (DIDS) has been used in clinic during the past 30 years as an inhibitor of anion transporters and channels. Recently DIDS has been demonstrated to affect Rad51-mediated homologous pairing and strand exchange, key processes in homologous recombination. Consequently, DIDS has been considered as a potential revertant of radio- and chemo-resistance of cancer cells, the major causes of therapy failure. Here, we have investigated the behavior of DIDS towards serum albumins. The effects of environmental factors, primarily, solvent polarity, on DIDS stability were evaluated, and the mechanisms of interaction of DIDS with human or bovine serum albumin were analyzed using isothermal calorimetry, circular dichroism and fluorescence spectroscopies. DIDS interaction with both serum albumins have been demonstrated, and the interaction characteristics have been determined. By comparing these characteristics for several DIDS derivatives, we have identified the DIDS moiety essential for the interaction. Furthermore, site competition data indicate that human albumin has two DIDS-binding sites: a high-affinity site in the IIIA subdomain and a low-affinity one in the IB subdomain. Molecular docking has revealed the key molecular moieties of DIDS responsible for its interactions in each site and shown that the IB site can bind two ligands. These findings show that binding of DIDS to serum albumin may change the balance between the free and bound DIDS forms, thereby affecting its bioavailability and efficacy against Rad51.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
1 publication
Lafont, Florian; Ayadi, Nizar; Charlier, Cathy; Weigel, Pierre; Nabiev, Igor; Benhelli-Mokrani, Houda; Fleury, Fabrice
Assessment of DNA-PKcs kinase activity by quantum dot–based microarray Article de journal
Dans: Scientific Reports, vol. 8, no. 1, p. 1–12, 2018, ISSN: 20452322.
@article{Lafont2018,
title = {Assessment of DNA-PKcs kinase activity by quantum dot–based microarray},
author = {Florian Lafont and Nizar Ayadi and Cathy Charlier and Pierre Weigel and Igor Nabiev and Houda Benhelli-Mokrani and Fabrice Fleury},
doi = {10.1038/s41598-018-29256-2},
issn = {20452322},
year = {2018},
date = {2018-01-01},
journal = {Scientific Reports},
volume = {8},
number = {1},
pages = {1--12},
abstract = {Therapeutic efficacy against cancer is often based on a variety of DNA lesions, including DNA double-strand breaks (DSBs) which are repaired by homologous recombination and non-homologous end joining (NHEJ) pathways. In the past decade, the functions of the DNA repair proteins have been described as a potential mechanism of resistance in tumor cells. Therefore, the DNA repair proteins have become targets to improve the efficacy of anticancer therapy. Given the central role of DNA-PKcs in NHEJ, the therapeutic efficacy of targeting DNA-PKcs is frequently described as a strategy to prevent repair of treatment-induced DNA damage in cancer cells. The screening of a new inhibitor acting as a sensitizer requires the development of a high-throughput tool in order to identify and assess the most effective molecule. Here, we describe the elaboration of an antibody microarray dedicated to the NHEJ pathway that we used to evaluate the DNA-PKcs kinase activity in response to DNA damage. By combining a protein microarray with Quantum-Dot detection, we show that it is possible to follow the modification of phosphoproteomic cellular profiles induced by inhibitors during the response to DNA damage. Finally, we discuss the promising tool for screening kinase inhibitors and targeting DSB repair to improve cancer treatment.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
1 publication
Bosseboeuf, Adrien; Feron, Delphine; Tallet, Anne; Rossi, Cédric; Charlier, Cathy; Garderet, Laurent; Caillot, Denis; Moreau, Philippe; Cardó-Vila, Marina; Pasqualini, Renata; Arap, Wadih; Nelson, Alfreda Destea; Wilson, Bridget S; Perreault, Hélène; Piver, Eric; Weigel, Pierre; Girodon, François; Harb, Jean; Bigot-Corbel, Edith; Hermouet, Sylvie
Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens Article de journal
Dans: JCI Insight, vol. 2, no. 19, p. 1–18, 2017, ISSN: 0021-9738.
@article{Bosseboeuf2017,
title = {Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens},
author = {Adrien Bosseboeuf and Delphine Feron and Anne Tallet and Cédric Rossi and Cathy Charlier and Laurent Garderet and Denis Caillot and Philippe Moreau and Marina Cardó-Vila and Renata Pasqualini and Wadih Arap and Alfreda Destea Nelson and Bridget S Wilson and Hélène Perreault and Eric Piver and Pierre Weigel and François Girodon and Jean Harb and Edith Bigot-Corbel and Sylvie Hermouet},
doi = {10.1172/jci.insight.95367},
issn = {0021-9738},
year = {2017},
date = {2017-01-01},
journal = {JCI Insight},
volume = {2},
number = {19},
pages = {1--18},
abstract = {Subsets of mature B cell neoplasms are linked to infection with intracellular pathogens such as Epstein-Barr virus (EBV), hepatitis C virus (HCV), or Helicobacter pylori. However, the association between infection and the immunoglobulin-secreting (Ig-secreting) B proliferative disorders remains largely unresolved. We investigated whether the monoclonal IgG (mc IgG) produced by patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma (MM) targets infectious pathogens. Antigen specificity of purified mc IgG from a large patient cohort (n = 244) was determined using a multiplex infectious-antigen array (MIAA), which screens for reactivity to purified antigens or lysates from 9 pathogens. Purified mc IgG from 23.4% of patients (57 of 244) specifically recognized 1 pathogen in the MIAA. EBV was the most frequent target (15.6%), with 36 of 38 mc IgGs recognizing EBV nuclear antigen-1 (EBNA-1). MM patients with EBNA-1-specific mc IgG (14.0%) showed substantially greater bone marrow plasma cell infiltration and higher β2-microglobulin and inflammation/infection-linked cytokine levels compared with other smoldering myeloma/MM patients. Five other pathogens were the targets of mc IgG: herpes virus simplex-1 (2.9%), varicella zoster virus (1.6%), cytomegalovirus (0.8%), hepatitis C virus (1.2%), and H. pylori (1.2%). We conclude that a dysregulated immune response to infection may underlie disease onset and/or progression of MGUS and MM for subsets of patients.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
1 publication
Martin-Jézéquel, Véronique; Calu, Guillaume; Candela, Leo; Amzil, Zouher; Jauffrais, Thierry; Séchet, Véronique; Weigel, Pierre
Effects of organic and inorganic nitrogen on the growth and production of domoic acid by pseudo-nitzschia multiseries and p. Australis (bacillariophyceae) in culture Article de journal
Dans: Marine Drugs, vol. 13, no. 12, p. 7067–7086, 2015, ISSN: 16603397.
@article{Martin-Jezequel2015,
title = {Effects of organic and inorganic nitrogen on the growth and production of domoic acid by pseudo-nitzschia multiseries and p. Australis (bacillariophyceae) in culture},
author = {Véronique Martin-Jézéquel and Guillaume Calu and Leo Candela and Zouher Amzil and Thierry Jauffrais and Véronique Séchet and Pierre Weigel},
doi = {10.3390/md13127055},
issn = {16603397},
year = {2015},
date = {2015-12-01},
journal = {Marine Drugs},
volume = {13},
number = {12},
pages = {7067--7086},
publisher = {MDPI AG},
abstract = {Over the last century, human activities have altered the global nitrogen cycle, and anthropogenic inputs of both inorganic and organic nitrogen species have increased around the world, causing significant changes to the functioning of aquatic ecosystems. The increasing frequency of Pseudo-nitzschia spp. in estuarine and coastal waters reinforces the need to understand better the environmental control of its growth and domoic acid (DA) production. Here, we document Pseudo-nitzschia spp. growth and toxicity on a large set of inorganic and organic nitrogen (nitrate, ammonium, urea, glutamate, glutamine, arginine and taurine). Our study focused on two species isolated from European coastal waters: P. multiseries CCL70 and P. australis PNC1. The nitrogen sources induced broad differences between the two species with respect to growth rate, biomass and cellular DA, but no specific variation could be attributed to any of the inorganic or organic nitrogen substrates. Enrichment with ammonium resulted in an enhanced growth rate and cell yield, whereas glutamate did not support the growth of P. multiseries. Arginine, glutamine and taurine enabled good growth of P. australis, but without toxin production. The highest DA content was produced when P. multiseries grew with urea and P. australis grew with glutamate. For both species, growth rate was not correlated with DA content but more toxin was produced when the nitrogen source could not sustain a high biomass. A significant negative correlation was found between cell biomass and DA content in P. australis. This study shows that Pseudo-nitzschia can readily utilize organic nitrogen in the form of amino acids, and confirms that both inorganic and organic nitrogen affect growth and DA production. Our results contribute to our understanding of the ecophysiology of Pseudo-nitzschia spp. and may help to predict toxic events in the natural environment.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}